14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AMD vs MXCT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Advanced Micro Devices (AMD) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AMD carries a Unified Composite Score of 62.6/100 (BUY) at $424.39 (24.1x Forward P/E, 17.8% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin).
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AMD vs MXCT Key Questions & Quantitative Answers
As of Nov 20, 2026, Advanced Micro Devices (AMD) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AMD carries a Unified Composite Score of 62.6/100 (BUY) at $424.39 (24.1x Forward P/E, 17.8% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin). Technically, AMD sits in a Neutral phase (RSI 38.4, CONSOLIDATION options structure) and MXCT sits in a Markup phase (RSI 55.3, UNCLASSIFIED options structure).
AMD leads the Growth & Scale pillar: AMD posts +44.7% YoY revenue growth and +93.8% YoY earnings growth on $45.4B TTM revenue (56.0% gross margin, 17.8% operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AMD cumulative revenue shifted +435.4% while MXCT shifted +100.0%. In operating R&D and SG&A reinvestment, AMD deploys 38.2% of Rev ($17.4B) (7 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.
AMD screens cheaper on headline valuation multiples. AMD trades at 24.1x Forward P/E, 104.5x Trailing P/E, 0.47x PEG, and 17.9x EV/Revenue (15.5% FCF margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMD (12.0% ROE) versus MXCT (-16.9% ROE) capital efficiency.
In options market volatility and institutional positioning, AMD carries 87.2% implied volatility (11th %ile, Compressed (<25th %ile)), a 1.31x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.65β · 124% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.